RSS-Feed abonnieren
DOI: 10.1055/s-2003-45125
Early Detection and Intervention in the Initial Prodromal Phase of Schizophrenia
Publikationsverlauf
Publikationsdatum:
15. Dezember 2003 (online)
Attenuated and transient psychotic symptoms as well as a combination of different risk indicators and a recent significant deterioration in global functioning are currently used as a preliminary definition of the initial prodromal or at-risk mental state by the vast majority of investigators in research on early psychosis detection and intervention. Recently published results demonstrated a mean progression to frank psychosis within one year in 36.7 % of cases showing emerging symptoms, indicating that these criteria already seem to provide a satisfying assessment for risk of an imminent psychosis. However, as functional decline often sets in before this time, detection in earlier prodromal stages seems necessary. In a prospective study, certain basic cognitive and perceptive symptoms showed good to excellent predictive accuracy for schizophrenic psychosis, thus potentially offering a reasonable approach for earlier detection. Early intervention is aimed at improving prodromal symptoms, avoiding functional deterioration, and suppressing or delaying transition to psychosis. Initial study results targeting an earlier or later prodromal phase are promising, but longer follow-ups and larger samples are needed.
Key words
Psychosis - Schizophrenia - Early detection - Early intervention - Prodrome
References
- 1 Addington D, Addington J, Patten S. Depression in people with first-episode schizophrenia. Br J Psychiatry. 1998; 172 (Suppl. 33) 90-92
-
2 American Psychiatric Association ( APA). Diagnostic and statistical manual of mental disorders. 3rd revised edition
DSM-III-R . Washington; APA 1987 -
3 American Psychiatric Association ( APA). Diagnostic and statistical manual of mental disorders. 4th edition
DSM-IV . Washington; APA 1994 - 4 Andreasen N C, Flaum M. Schizophrenia. The characteristic symptoms. Schizophr Bull. 1991; 17 27-49
- 5 Bechdolf A, Wagner M, Hambrecht M. Psychological intervention in the pre-psychotic phase: preliminary results of a multicentre trial. Acta Psychiatr Scand. 2002; 106 (Suppl. 413) 41
- 6 Birchwood M, McMillan J F. Early intervention in schizophrenia. Aust N Z J Psychiatry. 1993; 27 374-378
- 7 Brown S, Birtwistle J. People with schizophrenia and their families. Fifteen-year outcome. Br J Psychiatry. 1998; 173 139-144
- 8 Cornblatt B, Obuchowski M, Roberts S, Pollack S, Erlenmeyer-Kimling L. Cognitive and behavioural precursors of schizophrenia. Dev Psychopathol. 1999; 11 487-508
- 9 Cornblatt B. Early pharmacotherapeutic intervention in the prodromal phase of schizophrenia: Is this a good idea?. J Psychotic Disord. 2000; 4 3-15
- 10 Craig T J, Bromet E J, Fennig S, Tanenberg-Karant M, Lavelle J, Galambos N. Is there an association between duration of untreated psychosis and 24-month clinical outcome in first-admission series. Am J Psychiatry. 2000; 157 60-67
- 11 Falloon I RH. Early intervention for first episodes of schizophrenia: a preliminary exploration. Psychiatry. 1992; 55 4-15
- 12 Geddes J R, Verdoux H, Takei N, Lawrie S M, Bovet P, Eagles J M, Heun R, McCreadie R G, McNeil T F, O’Callaghan E, Stober G, Willinger U, Murray R M. Schizophrenia and complications of pregnancy and labor: an individual patient data meta-analysis. Schizophr Bull. 1999; 25 413-423
- 13 Gross G, Huber G, Klosterkötter J, Linz M. Bonner Skala für die Beurteilung von Basissymptomen (BSABS: Bonn Scale for the Assessment of Basic Symptoms). Berlin, Heidelberg, New York; Springer 1987
- 14 Haas G L, Garratt L S, Sweeney J A. Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness. J Psychiatr Res. 1998; 32 151-159
-
15 Häfner H, Maurer K, Löffler W, an der Heiden W, Könnecke R, Hambrecht M. The early course of schizophrenia. In Häfner H, editor
Risk and protective factors in schizophrenia - towards a conceptual model of the disease process . Darmstadt; Steinkopff 2002: p. 207-228 - 16 Hambrecht M, Häfner H. Substance abuse and the onset of schizophrenia. Biol Psychiatry. 1996; 39 1-9
- 17 Heinssen R K, Perkins D O, Appelbaum P S, Fenton W S. Informed consent in early psychosis research: National Institute of Mental Health Workshop, November 15, 2000. Schizophr Bull. 2001; 27 563-570
- 18 Helgason L. Twenty years’ follow-up of first psychiatric presentation for schizophrenia: What could have been prevented. Acta Psychiatr Scand. 1990; 81 231-235
- 19 Ho B C, Andreasen N C, Flaum M, Nopoulos P, Miller D. Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia. Am J Psychiatry. 2000; 157 808-815
- 20 Hoff A L, Sakuma M, Razi K, Heydebrand G, Csernansky J G, DeLisi L E. Lack of association between duration of untreated illness and severity of cognitive and structural brain deficits at the first episode of schizophrenia. Am J Psychiatry. 2000; 157 1824-1828
-
21 Huber G. Psychiatrische Aspekte des Basisstörungskonzepts. In Süllwold L, Huber G, editors
Schizophrene Basisstörungen . Berlin, Heidelberg, New York; Springer 1986: p. 39-143 - 22 Huber G, Gross G, Schüttler R. Schizophrenie. Verlaufs- und sozialpsychiatrische Langzeituntersuchungen an den 1945 - 1959 in Bonn hospitalisierten schizophrenen Kranken. Berlin, Heidelberg, New York; Springer 1979
- 23 Huber G. Reine Defektsyndrome und Basisstadien endogener Psychosen. Fortschr Neurol Psychiatr. 1966; 34 409-426
- 24 Humphreys M S, Johnstone E C, MacMillan J F, Taylor P J. Dangerous behaviour preceding first admissions for schizophrenia. Br J Psychiatry. 1992; 161 501-505
- 25 Jackson H J, McGorry P D, Dakis J, Harrigan S, Henry L, Mihalopoulos C. The inter-rater and test-retest reliabilities of prodromal symptoms in first-episode psychosis. Aust N Z J Psychiatry. 1996; 30 498-504
- 26 Jackson H J, McGorry P D, McKenzie D. Prodromal symptoms of schizophrenia in first-episode psychosis. Prevalence and specificity. Compr Psychiatry. 1994; 36 241-250
- 27 Jaeschko R, Guyatt G H, Sackett D L. User’s guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients?. JAMA. 1994; 271 703-707
- 28 Johnstone E C, Crow T J, Johnson A L, McMillan J F. The Northwick Park study of first episodes of schizophrenia: I. Presentation of the illness and problems relating to admission. Br J Psychiatry. 1986; 148 115-120
- 29 Johnstone E C, Macmillan J F, Frith C D, Benn D K, Crow T J. Further investigation of the predictors of outcome following first schizophrenic episodes. Br J Psychiatry. 1990; 157 182-189
- 30 Klosterkötter J. Predicting the onset of schizophrenia. In Häfner H, editor. Risk and protective factors in schizophrenia - towards a conceptual model of the disease process. Darmstadt; Steinkopff 2002: p. 193-206
- 31 Klosterkötter J, Hellmich M, Steinmeyer E M, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry. 2001; 58 158-164
- 32 Koreen A R, Siris S G, Chakos M, Alvir J, Mayerhoff D, Lieberman J. Depression in first-episode schizophrenia. Am J Psychiatry. 1993; 150 1643-1648
- 33 Larsen T K, Johannessen J O, Opjordsmoen S. First-episode schizophrenia with long duration of untreated psychosis. Pathways to care. Br J Psychiatry. 1998; 172 (Suppl 33) 45-52
- 34 Larsen T K, McGlashan T H, Moe L C. First-episode schizophrenia: I. Early course parameters. Schizophr Bull. 1996; 22 241-256
- 35 Lieberman J A, Kinon B J, Loebel A D. Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophr Bull. 1990; 16 97-110
- 36 Lieberman J A, Sheitman B B, Kinon B J. Endogenous neurochemical sensitization in the pathophysiology of schizophrenia deficits and dysfunction in neural regulation and plasticity. Neuropsychopharmacology. 1997; 17 205-229
- 37 Loebel A D, Lieberman J A, Alvir J M, Mayerhoff D I, Geisler S H, Szymanski S R. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry. 1992; 149 1183-1188
- 38 Malla A K, Norman R MG. Facing the challenges of intervening early in psychosis. Annals RCPSC. 1999; 32 394-397
- 39 Malla A K, Norman R MG, Voruganti L P. Improving outcome in schizophrenia: the case for early intervention. Can Med Assoc J. 1999; 160 843-846
- 40 McGlashan T H, Johannessen J O. Early detection and intervention with schizophrenia: rationale. Schizophr Bull. 1996; 22 201 -222
- 41 McGlashan T H, Miller T J, Woods S W. Pre-onset detection and intervention research in schizophrenia psychoses: current estimates of benefit and risk. Schizophr Bull. 2001; 27 563-570
- 42 McGorry P D, Edwards J. Early psychosis training pack. Victoria Mill; Gardiner-Caldwell Communications, Australia 1997
- 43 McGorry P D, Edwards J, Mihalopoulos S M. EPPIC: An evolving system of early detection and optimal management. Schizophr Bull. 1996; 22 305-326
- 44 McGorry P D, McKenzie D, Jackson H J, Waddell F, Curry C. Can we improve the diagnostic efficiency and predictive power of prodromal symptoms for schizophrenia?. Schizophr Res. 2000; 42 91-100
- 45 McGorry P D, Yung A R, Phillips L J, Yuen H P, Francey S, Cosgrave E M, Germano D, Bravin J, Adlard S, McDonald T, Blair A, Jackson H. A randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002; 59 921-928
- 46 Miller T J, Zipursky R B, Perkins D. et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the ”prodromal” sample. Schizophr Res. 2003; 61 19-30
- 47 Morrison T, Bentall R, French P, Kilcommons A, Green J, Lewis S. Early detection and intervention for psychosis in primary care. Acta Psychiatr Scand. 2002; 106 (Suppl. 413) 44
- 48 Norman R MG, Townsend L, Malla A K. Duration of untreated psychosis and cognitive functioning in first episode patients. Br J Psychiatry. 2001; 179 340-345
- 49 Pantelis C, Velakoulis D, McGorry P D, Wood S J, Suckling J, Phillips L J, Yung A R, Bullmore E T, Brewer W, Soulsby B, Desmond P, McGuire P. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet. 2003; 361 281-288
- 50 Phillips L J, Yung A, McGorry P D. Identification of young people at risk of psychosis: validation of the personal assessment and crisis evaluation clinic intake criteria. Aust N Z J Psychiatry. 2000; 34 (Suppl.) S164-S169
- 51 Ruhrmann S, Kühn K U, Streit M, Bottlender R, Maier W, Klosterkötter J. Pharmakologische und psychologische Frühintervention bei Risikopersonen mit psychosenahen Prodromen: erste Ergebnisse einer kontrollierten Studie. Nervenarzt. 2002; 73 (Suppl. 1) 9
-
52 Schultze-Lutter F. Prediction of psychosis is necessary and possible. In McDonald C, Schulze K, Murray R, Wright P, editors
Schizophrenia: challenging the orthodox . Martin Dunitz (in press) - 53 Stirling J. et al . Expressed emotion and early onset schizophrenia: a one-year follow-up. Psychol Med. 1991; 21 675-685
- 54 Stirling J, Tantam D, Thomas P, Newby D, Montague L, Ring N, Rowe S. Expressed emotion and schizophrenia: the ontogeny of EE during an 18-month follow-up. Psychol Med. 1993; 23 771-778
- 55 Strakowski S M, Keck PE J r, McElroy S L, Lonczak H S, West S A. Chronology of comorbid and principal syndromes in first-episode psychosis. Compr Psychiatry. 1995; 36 106-112
- 56 Tsuang M T, Stone W S, Seidman L J, Faraone S V, Zimmet S, Wojcik J, Kelleher J P, Green A I. Treatment of nonpsychotic relatives of patients with schizophrenia: four case studies. Biol Psychiatry. 1999; 45 1412-1418
- 57 Warner R. The prevention of schizophrenia: What interventions are safe and effective. Schizophr Bull. 2001; 27 551-562
- 58 Wing J K, Cooper J F, Sartorius N. Measurement and classification of psychiatric symptoms. An Introduction manual for PSE and Catego-program. London; Cambridge Press 1974
- 59 Woods S W, Miller T J, McGlashan T H. The ‘prodromal’ patient: Both, symptomatic and at risk. CNS Spectr. 2001; 6 223-232
- 60 Woods S W, Breier A, Zipursky R B, Perkins D O, Addington J, Miller T J, Hawkins K A, Marquez E, Lindborg S R, Tohen M, McGlashan T H. Randomized trial of olanzapine vs placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry. 2003; (in press)
- 61 Wyatt R J. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991; 17 325-51
Stephan Ruhrmann, M.D.
Department of Psychiatry and Psychotherapy
University of Cologne
Joseph-Stelzmann-Str. 9
50924 Cologne
Germany
Telefon: +49 (221) 478-40 24
Fax: +49 (221) 478-55 93
eMail: stephan.ruhrmann@uni-koeln.de
URL: http://www.fetz.org